New cancer drug EVT801 tested in 32 patients – early safety results
NCT ID NCT05114668
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 27 times
Summary
This early-stage study tested a new oral drug called EVT801 in 32 adults with advanced solid tumours that no longer responded to standard treatments. The main goal was to check the drug's safety and find the best dose for future studies. The trial is now complete, and results will guide whether EVT801 moves into larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Léon Bérard
Lyon, 69373, France
-
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse, 31059, France
Conditions
Explore the condition pages connected to this study.